| Literature DB >> 31147367 |
Wei-Dong Lin1, Hai Deng1, Pi Guo2, Fang-Zhou Liu1, Ru-Yin Chen2, Xian-Hong Fang1, Xian-Zhang Zhan1, Hong-Tao Liao1, Wen-Xiang Huang1, Yang Liu1, Feng Wang1, Mu-Rui Zheng3, Hua-Zhang Liu3, Jun Huang1, Wei Wei1, Yu-Mei Xue1, Shu-Lin Wu1.
Abstract
OBJECTIVES: There are country and regional variations in the prevalence of hyperuricaemia (HUA). The prevalence of HUA and non-valvular atrial fibrillation (NVAF) in southern China is unknown.Entities:
Keywords: cardiac epidemiology; cardiology; epidemiology
Year: 2019 PMID: 31147367 PMCID: PMC6549638 DOI: 10.1136/bmjopen-2018-028007
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Baseline characteristics of residents with or without HUA
| Total | HUA | No HUA | P value | |
| Clinical characteristics | ||||
| Male (n, %) | 4047 (35.2) | 1814 (39.9) | 2233 (32.2) | <0.01 |
| Age (years) | 58.22±11.74 | 59.98±11.44 | 57.06±11.79 | <0.01 |
| Urban (n, %) | 5403 (46.9) | 2210 (48.6) | 3193 (46.0) | 0.01 |
| Systolic BP (mm Hg) | 130.51±20.52 | 134.16±20.39 | 128.13±20.25 | <0.01 |
| Diastolic BP (mm Hg) | 80.70±11.61 | 82.30±11.60 | 79.62±11.49 | <0.01 |
| Non-valvular AF (n, %) | 144 (1.3) | 91 (2.0) | 53 (0.8) | <0.01 |
| Hypertension (n, %) | 3377 (29.4) | 1744 (38.4) | 1633 (23.5) | <0.01 |
| Diabetes mellitus (n, %) | 1050 (9.1) | 528 (11.6) | 522 (7.5) | <0.01 |
| Elevated BP (n, %)* | 6698 (58.3) | 3092 (68.0) | 3606 (52.0) | <0.01 |
| BMI (kg/m2) | 24.01±3.55 | 25.08±3.55 | 23.32±3.37 | <0.01 |
| Abdominal circumference (cm) | 84.41±10.10 | 87.69±9.61 | 82.26±9.83 | <0.01 |
| Male | 84.41±10.11 | 87.71±9.63 | 82.26±9.83 | <0.01 |
| Female | 82.76±9.98 | 86.36±9.64 | 80.66±9.56 | <0.01 |
| Central obesity (n, %)† | 6183 (53.8) | 2984 (65.6) | 3199 (46.1) | <0.01 |
| Heart failure (n, %) | 114 (1.0) | 50 (1.1) | 64 (0.9) | 0.39 |
| Stroke/TIA (n, %) | 274 (2.4) | 128 (2.8) | 146 (2.1) | 0.02 |
| Alcohol consumption (n, %) | 2467 (21.5) | 1060 (23.3) | 1391 (20.0) | <0.01 |
| Smoking (n, %) | 2451 (21.3) | 1114 (24.5) | 1353 (19.5) | <0.01 |
| Laboratory examinations | ||||
| HGB (g/L) | 138.74±14.07 | 140.14±14.11 | 137.83±13.97 | <0.01 |
| PLT (109/L) | 243.78±60.67 | 245.42±61.76 | 242.71±59.93 | 0.019 |
| RBC (1012/L) | 4.76±0.64 | 4.80±0.65 | 4.73±0.63 | <0.01 |
| HDL cholesterol(mmol/L) | 1.49±0.55 | 1.36±0.51 | 1.58±0.56 | <0.01 |
| Reduced HDL cholesterol (n, %)‡ | 2589 (22.5) | 1369 (30.1) | 1220 (17.6) | <0.01 |
| LDL (mmol/L) | 3.64±1.03 | 3.72±1.04 | 3.58±1.01 | <0.01 |
| CHOL (mmol/L) | 5.486±1.13 | 5.57±1.17 | 5.42±1.11 | <0.01 |
| TG (mmol/L) | 1.696±1.43 | 1.47±1.06 | 2.05±1.18 | <0.01 |
| Raised TG level (n, %)§ | 3787 (33.0) | 2140 (47.1) | 1647 (23.7) | <0.01 |
| FPG (mmol/L) | 5.586±1.57 | 5.69±1.52 | 5.51±1.60 | <0.01 |
| Elevated FPG (n, %)¶ | 3375 (29.4) | 1653 (36.4) | 1722 (24.8) | <0.01 |
| Uric acid (μmol/L) | 367.20±98.39 | 460.60±72.77 | 306.01±55.62 | <0.01 |
| Male | 367.00±98.30 | 460.60±72.70 | 306.01±55.63 | <0.01 |
| Female | 340.76±89.40 | 434.37±64.43 | 286.30±46.52 | <0.01 |
| Creatinine (μmol/L) | 76.89±25.45 | 83.78±33.25 | 72.36±17.22 | <0.01 |
*Elevated BP was defined as systolic BP >130 or diastolic BP >85 mm Hg or history of hypertension.
†Central obesity was defined as waist circumference >85 cm for men and >80 cm for women.
‡Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific treatment for this lipid abnormality.
§Raised TG level was defined as TG >150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality.
¶Elevated FPG was defined as fasting plasma glucose >100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.
AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; CHOL, cholesterol; FPG, fasting plasma glucose; HDL, high-density lipoprotein; HGB, haemoglobin; HUA, hyperuricaemia; LDL, low-density lipoprotein; PLT, platelet; RBC, red blood cell; TG, triglycerides; TIA, transient ischaemic attack.
Figure 1Differential prevalence of hyperuricaemia (HUA) among men and women across 10-year age intervals starting at 35.
Figure 2Prevalence of hyperuricaemia in urban and rural areas.
Analysis of prevalence risk of HUA in multiple logistic regression model
| Model* | ORs | 95% CI | P value |
| Age (per 10 years) | 1.10 | 1.06 to 1.14 | <0.01 |
| Living area (urban) | 1.15 | 1.06 to 1.25 | <0.01 |
| Alcohol consumption | 1.12 | 1.01 to 1.24 | 0.03 |
| Central obesity† | 1.82 | 1.67 to 1.99 | <0.01 |
| Elevated FPG‡ | 1.18 | 1.08 to 1.29 | <0.01 |
| Elevated BP§ | 1.34 | 1.22 to 1.46 | <0.01 |
| Reduced HDL¶ | 1.27 | 1.15 to 1.41 | <0.01 |
| Raised TG level** | 2.14 | 1.96 to 2.35 | <0.01 |
*Adjusted risk factors: age (per 10 years), living region, education level, marriage status, smoking status, alcohol consumption, central obesity, elevated FPG, elevated BP, reduced HDL, raised TG level.
†Central obesity was defined as waist circumference >85 cm for men and >80 cm for women.
‡Elevated FPG was defined as fasting plasma glucose >100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes.
§Elevated BP was defined as systolic BP >130 mm Hg or diastolic BP >85 mm Hg or history of hypertension.
¶Reduced HDL was defined as HDL <40 mg/dL (1.03 mmol/L) in men or <50 mg/dL (1.29 mmol/L) in women or specific treatment for this lipid abnormality.
**Raised TG level was defined as triglycerides >150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality.
BP, blood pressure,; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.
Increasing OR for non-valvular atrial fibrillation with HUA
| Variables* | ORs | 95% CI | P value |
| Age (per 10 years) | 2.31 | 1.93 to 2.78 | <0.01 |
| Gender (female) | 2.21 | 1.45 to 3.36 | <0.01 |
| Central obesity | 1.93 | 1.29 to 2.87 | <0.01 |
| HUA | 2.19 | 1.53 to 3.12 | <0.01 |
| Heart failure | 5.13 | 2.53 to 10.43 | <0.01 |
*Adjusted risk factors: age (per 10 years), gender, heart failure, smoking status, alcohol consumption, central obesity, elevated FPG, elevated BP, reduced HDL, raised TG level and HUA.
BP, blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein, HUA, hyperuricaemia; TG, triglycerides.
Figure 3Receiver operating characteristic curves for determination of predictive value of hyperuricaemia (HUA) or serum uric acid (SUA) for atrial fibrillation in men (A) and women (B). Area under curve.